Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult~* rheumatoid arthritis~* group 1: initiating etanercept as first biologic therapy~* group 2: DAS28\<4.2, biologic naive and treated with non-biologic DMARDs~Exclusion Criteria:~* diagnosis of other inflammatory arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: None): adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
- nbDMARD (Type: None): biologic-naive adult rheumatoid arthritis patients with DAS28 \>4.2 treated with non-biologic anti-rheumatic drugs(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).